Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis
暂无分享,去创建一个
[1] R. Cady,et al. Efficacy and Safety of Eptinezumab in Patients With Chronic Migraine: PROMISE-2. , 2023, Neurology.
[2] D. García‐Azorín,et al. Persistence, use of resources and costs in patients under migraine preventive treatment: the PERSEC study , 2022, The Journal of Headache and Pain.
[3] M. Silvestrini,et al. Atogepant for the Prevention of Episodic Migraine in Adults: A Systematic Review and Meta-Analysis of Efficacy and Safety , 2022, Neurology and Therapy.
[4] S. Sacco,et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update , 2022, The Journal of Headache and Pain.
[5] L. Bendtsen,et al. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study , 2022, The Journal of Headache and Pain.
[6] L. Edvinsson. Iron deficiency screening is a key issue in chronic inflammatory diseases: A call of actions. , 2022, Journal of internal medicine.
[7] Zhong Wang,et al. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials , 2022, The Journal of Headache and Pain.
[8] Shuu-Jiun Wang,et al. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials , 2021, Neurotherapeutics.
[9] R. Lipton,et al. Atogepant for the Preventive Treatment of Migraine. , 2021, The New England journal of medicine.
[10] K. Hirata,et al. Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients , 2021, Headache.
[11] Miki Ishida,et al. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients , 2021, Headache.
[12] Shuu-Jiun Wang,et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study , 2021, Cephalalgia : an international journal of headache.
[13] K. Hirata,et al. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study , 2021, Headache.
[14] P. Pozo‐Rosich,et al. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study , 2021, Journal of Neurology.
[15] C. You,et al. Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis , 2021, Frontiers in Pharmacology.
[16] R. Cady,et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial , 2021, BMC Neurology.
[17] D. Dodick,et al. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene‐related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study , 2021, Headache.
[18] S. Silberstein,et al. Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial , 2021, European journal of neurology.
[19] R. Lipton,et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial , 2020, The Lancet.
[20] Eun Sug Park,et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.
[21] S. Aurora,et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial , 2020, The Lancet Neurology.
[22] A. Szegedi,et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial , 2020, The Lancet Neurology.
[23] R. Lipton,et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults , 2020, Cephalalgia : an international journal of headache.
[24] J. Olesen,et al. Two‐Hour CGRP Infusion Causes Gastrointestinal Hyperactivity: Possible Relevance for CGRP Antibody Treatment , 2020, Headache.
[25] A. Maassenvandenbrink,et al. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. , 2020, Pharmacology & therapeutics.
[26] R. Cady,et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) , 2020, Cephalalgia : an international journal of headache.
[27] Gaigai Li,et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis , 2019, BMC Neurology.
[28] R. Lipton,et al. Does Mindfulness‐Based Cognitive Therapy for Migraine Reduce Migraine‐Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial , 2019, Headache.
[29] H. Diener,et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial , 2019, The Lancet.
[30] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[31] Gerta Rücker,et al. Network meta‐analysis of rare events using the Mantel‐Haenszel method , 2019, Statistics in medicine.
[32] The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice , 2018, Headache.
[33] M. Ferrari,et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study , 2018, The Lancet.
[34] R. Conley,et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial , 2018, JAMA neurology.
[35] M. Matharu,et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial , 2018, Cephalalgia : an international journal of headache.
[36] S. Silberstein,et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial , 2018, JAMA.
[37] R. Lipton,et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults , 2018, Cephalalgia : an international journal of headache.
[38] D. Dodick,et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.
[39] Theo Vos,et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? , 2018, The Journal of Headache and Pain.
[40] T. Steiner,et al. Poor medical care for people with migraine in Europe – evidence from the Eurolight study , 2018, The Journal of Headache and Pain.
[41] M. Arnold. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition , 2018, Cephalalgia : an international journal of headache.
[42] P. Goadsby,et al. A Controlled Trial of Erenumab for Episodic Migraine , 2017, The New England journal of medicine.
[43] S. Silberstein,et al. Fremanezumab for the Preventive Treatment of Chronic Migraine , 2017, The New England journal of medicine.
[44] Tianjing Li,et al. Network meta-analysis: an introduction for clinicians , 2017, Internal and Emergency Medicine.
[45] Hossam M. Hammady,et al. Rayyan—a web and mobile app for systematic reviews , 2016, Systematic Reviews.
[46] H. Diener,et al. New therapeutic approaches for the prevention and treatment of migraine , 2015, The Lancet Neurology.
[47] Gerta Rücker,et al. Ranking treatments in frequentist network meta-analysis works without resampling methods , 2015, BMC Medical Research Methodology.
[48] S. Silberstein,et al. Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention , 2015, Headache.
[49] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[50] L. Bloudek,et al. Systematic Review of Migraine Prophylaxis Adherence and Persistence , 2014, Journal of managed care pharmacy : JMCP.
[51] R. Ohrbach,et al. The International Classification of Headache Disorders, 3rd edition (beta version) , 2013, Cephalalgia : an international journal of headache.
[52] W. Becker,et al. Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS‐II) , 2013, Headache.
[53] J. Olesen. The International Classification of Headache Disorders , 2008, Headache.
[54] R. Lipton,et al. Migraine prevalence, disease burden, and the need for preventive therapy , 2007, Neurology.
[55] Alexander J Sutton,et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.
[56] S. Aurora,et al. Galcanezumab in chronic migraine The randomized, double-blind, placebo-controlled REGAIN study , 2022 .